Search Results

Mestag Therapeutics and VIB announced entering into an agreement under which Mestag obtains the exclusive worldwide rights to research, develop and commercialize a panel of single domain antibodies, also known as Nanobodies®, to an undisclosed target that plays a central role in anti-cancer immunity.

Oxurion NV announced that it received approximately $400,000 in an upfront payment following the exercise of an option by a third party to license a preclinical oncology asset previously owned by its subsidiary, Oncurious, which had recently been transferred to VIB.

VIB, Flanders’ leading life sciences institute, and Surface Oncology today announced jointly the publication of a study entitled, “Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27: Cell Reports,” in Cell Reports, a leading scientific journal.

ExeVir Bio announced the publication of a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike”.

VIB7734 potently depletedblood andtissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases

As the outbreak of the new coronavirus continues to spread, VIB scientists are quickly mobilizing to try to find a potential treatment for the viral infection.

Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique antibody that is capable of binding the virus that causes COVID-19 (SARS-CoV-2). The antibody was developed in collaboration with two research groups in the US.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, announced that Brian Reed, Ph.D., Head of Research at Quantum-Si, presented an update on the Company’s technology advancements at the Next-Generation Protein Analysis and Detection Conference.